Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more
Veracyte Inc (VCYT) - Total Liabilities
Latest total liabilities as of September 2025: $110.12 Million USD
Based on the latest financial reports, Veracyte Inc (VCYT) has total liabilities worth $110.12 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Veracyte Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Veracyte Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Veracyte Inc Competitors by Total Liabilities
The table below lists competitors of Veracyte Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
All Winner Technology Co Ltd
SHE:300458
|
China | CN¥687.62 Million |
|
Steadfast Group Limited
F:1S6
|
Germany | €3.80 Billion |
|
Tibet Huayu Mining Co Ltd
SHG:601020
|
China | CN¥3.95 Billion |
|
Silergy Corp
TW:6415
|
Taiwan | NT$5.38 Billion |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
USA | $370.09 Million |
|
AVIC Heavy Machinery Co Ltd
SHG:600765
|
China | CN¥14.85 Billion |
|
Ellington Financial Inc.
NYSE:EFC-PD
|
USA | $16.05 Billion |
|
Plug Power Inc
NASDAQ:PLUG
|
USA | $1.61 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Veracyte Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Veracyte Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Veracyte Inc (2011–2024)
The table below shows the annual total liabilities of Veracyte Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $124.07 Million | +75.23% |
| 2023-12-31 | $70.80 Million | -12.83% |
| 2022-12-31 | $81.22 Million | -11.05% |
| 2021-12-31 | $91.31 Million | +154.13% |
| 2020-12-31 | $35.93 Million | +0.49% |
| 2019-12-31 | $35.76 Million | -12.54% |
| 2018-12-31 | $40.88 Million | -1.35% |
| 2017-12-31 | $41.44 Million | -0.02% |
| 2016-12-31 | $41.45 Million | +72.48% |
| 2015-12-31 | $24.03 Million | +2.42% |
| 2014-12-31 | $23.46 Million | +1.20% |
| 2013-12-31 | $23.19 Million | +63.68% |
| 2012-12-31 | $14.17 Million | +637.43% |
| 2011-12-31 | $1.92 Million | -- |